The Role of Hippo Pathway in Cancer Stem Cell Biology - PubMed (original) (raw)
Review
The Role of Hippo Pathway in Cancer Stem Cell Biology
Jae Hyung Park et al. Mol Cells. 2018.
Abstract
The biological significance and deregulation of the Hippo pathway during organ growth and tumorigenesis have received a surge of interest in the past decade. The Hippo pathway core kinases, MST1/2 and LATS1/2, are tumor suppressors that inhibit the oncogenic nuclear function of YAP/TAZ and TEAD. In addition to earlier studies that highlight the role of Hippo pathway in organ size control, cell proliferation, and tumor development, recent evidence demonstrates its critical role in cancer stem cell biology, including EMT, drug resistance, and self-renewal. Here we provide a brief overview of the regulatory mechanisms of the Hippo pathway, its role in cancer stem cell biology, and promising therapeutic interventions.
Keywords: Hippo pathway; YAP/TAZ; cancer stem cell; metastasis.
Figures
Fig. 1. Regulation of YAP and TAZ by the Hippo pathway
The core inhibitory kinase module of the Hippo pathway is composed of MST1/2, MAP4K, and LATS1/2. The transcriptional module is composed of YAP/TAZ and TEAD. (A) When the Hippo pathway is ‘off’, YAP/TAZ are dephosphorylated, accumulated, and they translocate into the nucleus to bind the transcription factors, TEAD1–TEAD4, which enable target gene transcription involved in cell proliferation. (B) When the Hippo pathway is turned ‘on’, LATS1/2 directly phosphorylate YAP/TAZ, which inhibit nuclear import of YAP/TAZ via 14-3-3-mediated cytoplasmic retention, and ubiquitination-mediated proteasomal and autolysosomal degradation. TEAD transcriptional activity is suppressed by VGLL4. LATS indicates large tumor suppressor; MST, mammalian STE20-like protein kinase; YAP, Yes-associated protein; TAZ, transcriptional co-activator with PDZ-binding motif; TEAD, TEA domain family members; VGLL4, transcription cofactor vestigial-like protein 4.
Fig. 2. Overview of YAP/TAZ regulation and function in cancer stem cells
The Hippo pathway regulates YAP/TAZ activation in cancer cells through a wide range of upstream stimuli, such as extracellular ligands, mechanotransduction, environmental stress, energy stress, and cell-cell contact. Aberrant activation of YAP/TAZ via dysregulation of the Hippo pathway results in tumorigenesis and confers cancer stem cell traits that lead to anoikis resistance, EMT, drug resistance, and metastasis.
Fig. 3. Therapeutic targeting of the Hippo pathway
Strategies for targeting Hippo-YAP/TAZ activity are indicated. Dasatinib, ROCK inhibitors, statins, GGTI (inhibitors of geranylgeranyl transferase-1) represent compounds that inhibit YAP/TAZ activity via activating LATS. Rapamycin, tankyrase inhibitors, metformin, 2-DG represent compounds that inhibit YAP/TAZ activity independent of LATS. Verteporfin and VGLL4-mimicking peptide represent compounds that inhibit the interaction between YAP/TAZ and TEAD. ROCK indicates Rho-associated protein kinase; FAK, focal adhesion kinase; PKA, protein kinase A; APC, adenomatous polyposis coli; AMPK, AMP-activated protein kinase; mTORC1, mechanistic target of rapamycin complex 1; RTK, receptor tyrosine kinase; GPCR, G-protein coupled receptor.
Similar articles
- Regulation of the Hippo pathway in cancer biology.
Moon S, Yeon Park S, Woo Park H. Moon S, et al. Cell Mol Life Sci. 2018 Jul;75(13):2303-2319. doi: 10.1007/s00018-018-2804-1. Epub 2018 Mar 30. Cell Mol Life Sci. 2018. PMID: 29602952 Free PMC article. Review. - The Hippo transducer TAZ promotes epithelial to mesenchymal transition and cancer stem cell maintenance in oral cancer.
Li Z, Wang Y, Zhu Y, Yuan C, Wang D, Zhang W, Qi B, Qiu J, Song X, Ye J, Wu H, Jiang H, Liu L, Zhang Y, Song LN, Yang J, Cheng J. Li Z, et al. Mol Oncol. 2015 Jun;9(6):1091-105. doi: 10.1016/j.molonc.2015.01.007. Epub 2015 Feb 9. Mol Oncol. 2015. PMID: 25704916 Free PMC article. - WWC proteins mediate LATS1/2 activation by Hippo kinases and imply a tumor suppression strategy.
Qi S, Zhu Y, Liu X, Li P, Wang Y, Zeng Y, Yu A, Wang Y, Sha Z, Zhong Z, Zhu R, Yuan H, Ye D, Huang S, Ling C, Xu Y, Zhou D, Zhang L, Yu FX. Qi S, et al. Mol Cell. 2022 May 19;82(10):1850-1864.e7. doi: 10.1016/j.molcel.2022.03.027. Epub 2022 Apr 15. Mol Cell. 2022. PMID: 35429439 - PAR1 participates in the ability of multidrug resistance and tumorigenesis by controlling Hippo-YAP pathway.
Fujimoto D, Ueda Y, Hirono Y, Goi T, Yamaguchi A. Fujimoto D, et al. Oncotarget. 2015 Oct 27;6(33):34788-99. doi: 10.18632/oncotarget.5858. Oncotarget. 2015. PMID: 26431277 Free PMC article. - Roles of RUNX in Hippo Pathway Signaling.
Passaniti A, Brusgard JL, Qiao Y, Sudol M, Finch-Edmondson M. Passaniti A, et al. Adv Exp Med Biol. 2017;962:435-448. doi: 10.1007/978-981-10-3233-2_26. Adv Exp Med Biol. 2017. PMID: 28299672 Free PMC article. Review.
Cited by
- ERK1 indicates good prognosis and inhibits breast cancer progression by suppressing YAP1 signaling.
Yu S, Zhang M, Huang L, Ma Z, Gong X, Liu W, Zhang J, Chen L, Yu Z, Zhao W, Liu Y. Yu S, et al. Aging (Albany NY). 2019 Dec 18;11(24):12295-12314. doi: 10.18632/aging.102572. Epub 2019 Dec 18. Aging (Albany NY). 2019. PMID: 31848326 Free PMC article. - Abnormal lipid synthesis as a therapeutic target for cancer stem cells.
Wang SY, Hu QC, Wu T, Xia J, Tao XA, Cheng B. Wang SY, et al. World J Stem Cells. 2022 Feb 26;14(2):146-162. doi: 10.4252/wjsc.v14.i2.146. World J Stem Cells. 2022. PMID: 35432735 Free PMC article. Review. - Research progress in breast cancer stem cells: characterization and future perspectives.
Mao XD, Wei X, Xu T, Li TP, Liu KS. Mao XD, et al. Am J Cancer Res. 2022 Jul 15;12(7):3208-3222. eCollection 2022. Am J Cancer Res. 2022. PMID: 35968346 Free PMC article. Review. - PI3K-Yap activity drives cortical gyrification and hydrocephalus in mice.
Roy A, Murphy RM, Deng M, MacDonald JW, Bammler TK, Aldinger KA, Glass IA, Millen KJ. Roy A, et al. Elife. 2019 May 16;8:e45961. doi: 10.7554/eLife.45961. Elife. 2019. PMID: 31094678 Free PMC article. - Co-regulatory Network of Oncosuppressor miRNAs and Transcription Factors for Pathology of Human Hepatic Cancer Stem Cells (HCSC).
Mohamed RH, Abu-Shahba N, Mahmoud M, Abdelfattah AMH, Zakaria W, ElHefnawi M. Mohamed RH, et al. Sci Rep. 2019 Apr 3;9(1):5564. doi: 10.1038/s41598-019-41978-5. Sci Rep. 2019. PMID: 30944375 Free PMC article.
References
- Aragona M., Panciera T., Manfrin A., Giulitti S., Michielin F., Elvassore N., Dupont S., Piccolo S. A mechanical checkpoint controls multicellular growth through YAP/TAZ regulation by actin-processing factors. Cell. 2013;154:1047–1059. - PubMed
- Azzolin L., Zanconato F., Bresolin S., Forcato M., Basso G., Bicciato S., Cordenonsi M., Piccolo S. Role of TAZ as Mediator of Wnt Signaling. Cell. 2012;151:1443–1456. - PubMed
- Azzolin L., Panciera T., Soligo S., Enzo E., Bicciato S., Dupont S., Bresolin S., Frasson C., Basso G., Guzzardo V., et al. YAP/TAZ incorporation in the beta-catenin destruction complex orchestrates the Wnt response. Cell. 2014;158:157–170. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous